Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: A study in Brazilian patients

Gene

Volumn 529, Issue 2, 2013, Pages 326-331

  Domenici, Fernanda Aparecida ^a   Brochado, Maria José Franco ^a   Martinelli, Ana de Lourdes Candolo ^a   Zucoloto, Sergio ^a   da Cunha, Selma Freire de Carvalho ^a   Vannucchi, Helio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

NASH; Nonalcoholic fatty liver disease; Polymorphism; PPAR

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IRON; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BRAZIL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENERGY; FEMALE; GENETIC RISK; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS;

NAFLD; NASH; NONALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; POLYMORPHISM; PPAR; SINGLE NUCLEOTIDE POLYMORPHISMS; SNPS;

ADULT; BRAZIL; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; PPAR GAMMA;

EID: 84883807198     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.06.091     Document Type: Article

References (55)

1. Abdelmalek M.F., et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 2001, 96(9):2711-2717.
2. Al-Shali K.Z., et al. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke 2004, 35(9):2036-2040.
3. Altshuler D., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 2000, 26(1):76-80.
4. Bedogni G., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42(1):44-52.
5. Bray G.A. Pathophysiology of obesity. Am. J. Clin. Nutr. 1992, 55(2 Suppl.):488S-494S.
6. Brunt E.M. Histopathology of non-alcoholic fatty liver disease. Clin. Liver Dis. 2009, 13(4):533-544.
7. Brunt E.M. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7(4):195-203.
8. Brunt E.M., et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53(3):810-820.
9. Chen S., et al. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J. Gastroenterol. Hepatol. 2008, 23(9):1415-1418.
10. Chen E.S., et al. Association of PPARalpha gene polymorphisms and lipid serum levels in a Brazilian elderly population. Exp. Mol. Pathol. 2010, 88(1):197-201.
11. Cheung O., Sanyal A.J. Recent advances in nonalcoholic fatty liver disease. Curr. Opin. Gastroenterol. 2009, 25(3):230-237.
12. Cotrim H.P., et al. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Ann. Hepatol. 2011, 10(1):33-37.
13. Das K., et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010, 51(5):1593-1602.
14. de Alwis N.M., Day C.P. Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatol. 2008, 48(Suppl. 1):S104-S112.
15. Deurenberg P., Yap M., van Staveren W.A. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int. J. Obes. Relat. Metab. Disord. 1998, 22(12):1164-1171.
16. Dongiovanni P., et al. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol. 2010, 10:102.
17. Fajas L., et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 1997, 272(30):18779-18789.
18. Fan J.G., et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. 2005, 43(3):508-514.
19. Flavell D.M., et al. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 2000, 43(5):673-680.
20. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18(6):499-502.
21. Gawrieh S., et al. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig. Dis. Sci. 2012, 57(4):952-957.
22. Genuth S., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26(11):3160-3167.
23. Gouda H.N., et al. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am. J. Epidemiol. 2010, 171(6):645-655.
24. Guidorizzi de Siqueira A.C., et al. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur. J. Gastroenterol. Hepatol. 2005, 17(8):837-841.
25. Gupta A.C., et al. Peroxisome proliferators-activated receptor gamma2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatol. Int. 2010, 5(1):575-580.
26. JAMA Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
27. Jamshidi Y., et al. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis 2002, 163(1):183-192.
28. Lohmueller K.E., et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 2003, 33(2):177-182.
29. Ludovico O., et al. Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk. Obesity (Silver Spring) 2007, 15(5):1076-1081.
30. Matteoni C.A., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
31. Mattevi V.S., Zembrzuski V.M., Hutz M.H. Effects of a PPARG gene variant on obesity characteristics in Brazil. Braz. J. Med. Biol. Res. 2007, 40(7):927-932.
32. Matthews D.R., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
33. Mazzotti D.R., et al. PPARalpha polymorphisms as risk factors for dyslipidemia in a Brazilian population. Mol. Genet. Metab. 2010, 102(2):189-193.
34. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16(3):1215.
35. Mori H., et al. The Pro12→Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001, 50(4):891-894.
36. Nielsen E.M., et al. Evidence for an association between the Leu162Val polymorphism of the PPARalpha gene and decreased fasting serum triglyceride levels in glucose tolerant subjects. Pharmacogenetics 2003, 13(7):417-423.
37. Parikh H., Groop L. Candidate genes for type 2 diabetes. Rev. Endocr. Metab. Disord. 2004, 5(2):151-176.
38. Paschos P., Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009, 13(1):9-19.
39. Petta S., Muratore C., Craxi A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig. Liver Dis. 2009, 41(9):615-625.
40. Radha V., et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: evidence for heterogeneity. Diabetes Care 2006, 29(5):1046-1051.
41. Rey J.W., et al. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma2 in patients with fatty liver diseases. World J. Gastroenterol. 2010, 16(46):5830-5837.
42. Robitaille J., et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J. Hum. Genet. 2004, 49(9):482-489.
43. Rotman Y., et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010, 52(3):894-903.
44. Sanguinetti C.J., Dias Neto E., Simpson A.J. Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques 1994, 17(5):914-921.
45. Sapone A., et al. The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 2000, 10(4):321-333.
46. Silbernagel G., et al. The L162V polymorphism of the peroxisome proliferator activated receptor alpha gene (PPARA) is not associated with type 2 diabetes, BMI or body fat composition. Exp. Clin. Endocrinol. Diabetes 2009, 117(3):113-118.
47. Smith B.W., Adams L.A. Non-alcoholic fatty liver disease. Crit. Rev. Clin. Lab. Sci. 2011, 48(3):97-113.
48. Tavares V., et al. Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes. Metab. 2005, 7(5):605-611.
49. Verdi H., et al. Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis. J. Investig. Med. 2005, 53(7):353-359.
50. Vieira-Filho J.P., et al. Influence of the polymorphisms Tpr64Arg in the beta 3-adrenergic receptor gene and Pro12Ala in the PPAR gamma 2 gene on metabolic syndrome-related phenotypes in an indigenous population of the Brazilian Amazon. Diabetes Care 2004, 27(2):621-622.
51. Vohl M.C., et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J. Lipid Res. 2000, 41(6):945-952.
52. Vuppalanchi R., Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009, 49(1):306-317.
53. Yen C.J., et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 1997, 241(2):270-274.
54. Yong E.L., Li J., Liu M.H. Single gene contributions: genetic variants of peroxisome proliferator-activated receptor (isoforms alpha, beta/delta and gamma) and mechanisms of dyslipidemias. Curr. Opin. Lipidol. 2008, 19(2):106-112.
55. Zelber-Sagi S., et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int. 2006, 26(7):856-863.